Sagimet Biosciences Inc. (SGMT) compared with its closest peers (AQST, STTK, EOLS, SPRY, OVID). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | $583.63M | -8.4 |
| Shattuck Labs, Inc. (STTK) | $578.55M | -5.2 |
| Evolus, Inc. (EOLS) | $554.49M | -8.3 |
| ARS Pharmaceuticals, Inc. (SPRY) | $546.17M | -6.7 |
| Ovid Therapeutics Inc. (OVID) | $545.86M | — |
| NovaBridge Biosciences (NBP) | $530.76M | -18.9 |
| Prelude Therapeutics Incorporated (PRLD) | $528.30M | -2.2 |
| MapLight Therapeutics, Inc. (MPLT) | $523.89M | -0.9 |
| Evommune, Inc. (EVMN) | $506.27M | -1.6 |
| XOMA Royalty Corp. (XOMA) | $505.65M | 16.8 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
SGMT overview · SGMT earnings · SGMT financials · SGMT KPIs · SGMT investor relations · SGMT ownership · SGMT filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.